

Indian policies to promote local production of pharmaceutical products and protect public health



IP
Intellectual
Property and Trade

R&D
Innovation

TF
Technology
Transfer

IA
Improving Access

FI
Financing

MR
Monitoring and
Reporting



European
Commission



World Health
Organization

Indian policies to promote local production of pharmaceutical products and protect public health



European
Commission



World Health
Organization

Indian policies to promote local production of pharmaceutical products and protect public health

ISBN 978-92-4-151221-3

© **World Health Organization 2017**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Indian policies to promote local production of pharmaceutical products and protect public health. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Editing and design by Inís Communication – www.iniscommunication.com

Photo: Esther Havens for the Sabin Vaccine Institute

Contents

Abbreviations and Acronyms	iv
Acknowledgements	vi
Executive Summary	1
Indian policies to promote local production of pharmaceutical products and protect public health	4
I. Statement of objective	4
II. Research methodology	4
III. Policies and programmes in India	5
IV. Summary of the Indian model	36
V. Extending the cluster concept to other geographies	39
Annex 1: Series of questions for India in preparation of this report	40
Annex 2: List of Government interviewees	44
Annex 3: Indian Government Institutions engaged in Pharma R&D	45
Annex 4: India Pharmaceuticals Working Group Report Summary of Dr Sen's report on access	47

Abbreviations and Acronyms

ABLE	Association of Biotechnology Led Enterprises
API	active pharmaceutical ingredient
BIG	Biotechnology Ignition Grant Scheme
BIPP	Biotechnology Industry Partnership Programme
BIRAC	Biotechnology Industry Research Assistance Council
CDSCO	Central Drug Standards Control Organization
CPSE	central public sector enterprise
CRAMS	contract research and manufacturing services
CRO	contract research organization
CRS	Contract Research and Services Scheme
CSIR	Council of Scientific and Industrial Research
DIPP	Department of Industrial Policy and Promotion
DoP	Department of Pharmaceuticals
EC	European Commission
EMA	European Medicines Agency
EML	essential medicines list
FDA	Food and Drug Administration
FDI	foreign direct investment
FPP	finished pharmaceutical product
FTZ	free trade zones
GATT	General Agreement on Tariffs and Trade 1994
GMP	good manufacturing practice
GPA	WTO Agreement on Government Procurement
GSPA	Global Strategy and Plan of Action
GST	goods and services tax
HIC	high-income countries
ICMR	Indian Council of Medical Research
IDMA	Indian Drug Manufacturers' Association
IPA	Indian Pharmaceutical Alliance
IP	intellectual property
IPR	intellectual property right
IT	information technology

JNPC	Jawaharlal Nehru Pharma City
LDC	least-developed countries
LMIC	low- and middle-income countries
MAT	minimum alternate tax
MPP	Medicines Patent Pool
MNC	multinational corporation
MRP	maximum retail price
NIH	National Institutes of Health
NIPER	National Institute of Pharmaceutical Education and Research
NPPA	National Pharmaceutical Pricing Authority
OECD	Organization for Economic Cooperation and Development
OPPI	Organization of Pharmaceutical Producers of India
OTC	over-the-counter
Pharmexcil	Pharmaceuticals Export and Promotion Council of India
PHI	Public Health, Innovation and Intellectual Property
PSUs	government-run pharmaceutical facilities
PTR	price to retailer
RMSC	Rajasthan Medical Services Corporation
REZ	regional economic zone
R&D	research and development
SEZ	special economic zone
SME	small and medium enterprise
SPV	special purpose vehicle
SSI	small-scale industry
TNMSC	Tamil Nadu Medical Services Corporation
TRIPS	Trade-Related Aspects of Intellectual Property Rights
UHC	universal health care
US PTO	United States Patent and Trademark Office
USP	United States Pharmacopeia Convention
VAT	value-added tax
WHO	World Health Organization
WTO	World Trade Organization

INDIA REPORT

Acknowledgements

This report was made possible by the generous support of the European Commission (EC) through the World Health Organization (WHO) local production project: *Improving access to medical products in developing countries through capacity building for local production and related technology transfer*. It was prepared by Professor Frederick Abbott, WHO Consultant.

Research underlying the report was facilitated by the hospitality of the Government of India, and through interview access to multiple government officials. Special thanks are due to Mr Rajeev Kher, former Secretary of the Department of Commerce, Ministry of Commerce & Industry of India, as well as to Mr Sudhanshu Pandey, Joint Secretary of the Department of Commerce, each of whom was instrumental in arranging the research programme in India. A list of the government officials who were interviewed is attached (Annex 2), each of whom is owed our gratitude.

The report benefited greatly from review and comments by Mr Dilip Shah, Secretary-General of the Indian Pharmaceutical Alliance, and from the review and comments of Professor Sudip Chaudhuri, Professor of Economics at the Indian Institute of Management in Calcutta.

This report was initiated under the direction of Dr Zafar Mirza, former Coordinator of the Programme on Public Health, Innovation and Intellectual Property, WHO Department of Essential Medicines and Health Products (EMP). Dr Jicui Dong, Programme Manager for Local Production, EMP, also contributed to this report, which was produced under the supervision of Dr Mirza and Dr Suzanne Hill, Director of the Department of Essential Medicines and Health Products.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26450

